Genocea Biosciences Announces Closing Of $50 Million Public Offering Of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the closing of the previously announced public offering of 3,850,000 shares of its common stock, at the public offering price of $13.00 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 577,500 shares of common stock at the same price. The net proceeds to Genocea from this offering are expected to be approximately $47 million.

Cowen and Company, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Needham & Company is acting as co-manager.

The offering was made pursuant to a shelf registration statement on Form S-3 made effective with the Securities and Exchange Commission (the “SEC”) on May 14, 2015, and a related final prospectus supplement filed on July 30, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy and there shall not be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

The final prospectus supplement and accompanying prospectus is available for free by visiting EDGAR on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained from Cowen and Company c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by calling (631) 274-2806, or by fax (631) 254-7140, Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by calling (800) 747-3924, or by emailing prospectus@pjc.com or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by calling (415) 364-2720, or by emailing syndprospectus@stifel.com.

About Genocea Biosciences, Inc.

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria. Genocea is also investigating the application of ATLAS™ to immuno-oncology target discovery.

Forward-Looking Statements

This press release includes forward-looking statements, including statements relating to the underwritten public offering. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea’s Annual Report on Form 10-K for the year ended December 31, 2014 and any subsequent SEC filings, including the registration statement and final prospectus supplement related to the offering. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements.